<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088241</url>
  </required_header>
  <id_info>
    <org_study_id>P002-17-1.0</org_study_id>
    <nct_id>NCT03088241</nct_id>
  </id_info>
  <brief_title>&quot;Switch Either Near Suppression Or THOusand&quot;</brief_title>
  <acronym>SESOTHO</acronym>
  <official_title>Switch to Second-line Versus WHO-guided Standard of Care for Unsuppressed Patients on First-line ART With Viremia Below 1000 Copies/mL - a Multicenter, Parallel-group, Open-label, Randomized Clinical Study in Rural Lesotho</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Manuel Battegay, Study Chair, University Hospital Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bienvenu Nsakala, MD, Co-Investigator &amp; Study Physician SolidarMed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Josephine Muhairwe, MD, MPH, Co-Investigator &amp; Country Coordinator SolidarMed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tracy Glass, PhD, Co-Investigator &amp; Statistician SwissTPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fiona Vanobberghen, PhD, Co-Investigator &amp; Statistician SwissTPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Thomas Klimkait, PhD, Co-Investigator, Department of Biomedicine, University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beatrice Achieng, Study nurse &amp; Clinical Officer, Butha-Buthe Hospital, Lesotho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mamorena Sepeka, Study nurse, Butha-Buthe Hospital, Lesotho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Katleho Tlali, MLS, Laboratory Technician Laboratory Butha-Buthe Hospital, Lesotho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lebohang Sao, MD, District Health Manager Butha-Buthe, Lesotho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyaw Thin, MD &amp; MPH, Head of Research Coordination Unit, Ministry of Health Lesotho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Tropical &amp; Public Health Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial addresses the question of the viral load (VL) threshold for switching from
      first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold
      at 1000 copies/mL. However, the optimal threshold for defining virological failure and the
      need to switch ART regimen has not been determined. In fact, people with VL levels of less
      than 1000 copies/mL, however, not fully suppressed, are at increased risk for drug resistance
      mutations (DRM) and subsequent virological failure. In resource-limited settings where VL
      monitoring is not as frequent as in high-income countries, this could have serious
      implications and patients may continue on a failing regimen for a long period. Our research
      consortium will conduct a multicenter, parallel-group, open-label, randomized clinical trial
      in a resource-limited setting to assess whether a threshold of 100 copies/mL compared to the
      WHO-defined threshold of 1000 copies/mL for switching to second-line ART among unsuppressed
      HIV-positive patients on first-line ART will lead to better outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study background &amp; rational:

      The Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the 90-90-90 targets for
      2020 based on the result of newly-acquired scientific evidence that - irrespective of CD4
      count - early antiretroviral treatment (ART) for HIV-positive individuals is beneficial to
      them and prevents HIV transmission. UNAIDS expects that the 90-90-90 targets will lead to a
      reduction in the yearly global HIV incidence from 2 million currently to 500,000 by 2020.

      A crucial step to achieve the third pillar of the UNAIDS 90-90-90 targets - 90% viral
      suppression among HIV-positive individuals on treatment - and thus ensure a successful
      treatment outcome is the monitoring and management of first-line ART failure.

      Since 2013, the WHO recommends routine viral load (rVL) measurement as the preferred
      monitoring strategy in resource-limited settings and defines virological failure as confirmed
      VL 1000 copies/mL despite good adherence. Specifically, the guidelines recommend that in case
      of a VL ≥ 1000 copies/mL the patient should undergo enhanced adherence support and a second
      VL test 3 months later. A second VL ≥ 1000 copies/mL with confirmed good adherence would
      trigger the switch to a second-line regimen, whereas if the VL is &lt; 1000 copies/mL the
      patient should continue unaltered first-line ART. However, the optimal threshold for defining
      virological failure and the need for switching ART regimen has not yet been determined. In
      fact, people with VL levels of less than 1000 copies/mL, but not fully suppressed (usually
      defined as 50-100 copies/mL), are at a increased risk for drug resistance mutations (DRM) and
      subsequent virological failure. A recently published study from our research consortium in
      Lesotho indicates similar findings, demonstrating a significant accumulation of drug
      resistance mutations in patients with VL levels of less than 1000 copies/mL.

      The VL threshold of 1000 copies/mL recommended by the WHO and the Lesotho national guidelines
      for the switch to second-line ART is likely to miss a substantial number of patients on
      first-line ART with persisting virus replication below 1000 copies/mL with DRM. In
      resource-limited settings where VL monitoring is not as frequent as in high-income countries,
      this could have serious implications: after a VL below 1000 copies/mL the patient may not
      receive a follow-up VL for up to a year, and thus may continue on a failing regimen for a
      long period of time. In conclusion, such patients are at increased risk for DRM, accumulation
      of further resistance mutations, drug-resistant virus transmission, and subsequent
      virological failure.

      Study hypothesis:

      Our research consortium hypothesizes that in patients on first-line ART with two consecutive
      unsuppressed VL measurements equal/more than 100 copies/mL, where the second VL is between
      100 and 999 copies/mL, switch to second-line ART (intervention group) will lead to a higher
      rate of viral resuppression (VL &lt; 50 copies/mL) and is therefore superior compared to not
      switching to second-line ART according to WHO guidelines (control group, standard of care).

      Study design:

      Multicenter (2-12 centers), parallel-group (1:1 allocation), open-label, superiority,
      prospective randomized clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter (2-12 centers), parallel-group (1:1 allocation), open-label, superiority, prospective randomized clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>viral suppression</measure>
    <time_frame>9 months after randomization</time_frame>
    <description>Proportion of virologically suppressed (VL &lt; 50 copies/mL) participants 9 months after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with different VL thresholds (VL &lt;100, &lt;200, &lt;400, &lt;1000 copies/mL) at 9 months after randomization</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence at 3, 6, 9 months, assessed by self-reported dose omission</measure>
    <time_frame>3, 6, 9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in values (versus values at baseline) of body-weight (kg) at 9 months</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in values (versus values at baseline) of haemoglobin (g/dL) at 9 months</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in values (versus values at baseline) of CD4 count (cells/mL) at 9 months</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in values (versus values at baseline) of lipids (total cholesterol, LDL, HDL, triglycerides; mmol/l) at 9 months</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in values (versus values at baseline) of new clinical WHO 3 or 4 events (proportion) count at 9 months</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in values (versus values at baseline) of deaths (all-causes) (proportion) at 9 months</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events and serious adverse events at 9 months after randomization</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term follow-up endpoint: Proportion of patients that are alive, retained in care and virologically suppressed (VL &lt; 50 copies/mL) at 24 months</measure>
    <time_frame>24 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of virologically suppressed (VL &lt; 50 copies/mL) participants by demographic groups (children vs pregnant women vs adults)</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of virologically suppressed (VL &lt; 50 copies/mL) participants by different VL groups at enrolment (VL 100-599 vs 600-999 copies/mL copies/mL)</measure>
    <time_frame>9 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with viral resuppression (&lt;50 copies/mL)</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic failure</measure>
    <time_frame>6 and 9 months after randomization</time_frame>
    <description>Proportion of participants with unsuppressed VL &gt;50 copies/mL at 6 and 9 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Direct costs of each treatment arm</measure>
    <time_frame>9 months and 24 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of major viral resistance mutations to first-line regimen in each treatment arm for all samples for which an RT-PCR amplification is successful</measure>
    <time_frame>9 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>pre-specified subgroup: Log-drop</measure>
    <time_frame>9 months after randomization</time_frame>
    <description>Viral resuppression among individuals with a &gt;0.5 drop in log10 VL between the first screening VL and the second screening VL (i.e. VL at enrolment)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switch to second-line ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care: no switch to second-line ART</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>switch</intervention_name>
    <description>switch to second-line ART</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On NNRTI-based first-line ART with two consecutive unsuppressed VL equal/more 100
             copies/mL, with the second VL between 100 and 999 copies/mL.

          -  Lives and/or works in the district of Butha-Buthe and declares to seek follow-up at
             one of the study-facilities

          -  Signed written informed consent. For children aged &lt;16 years, a main caregiver, and
             for illiterate a literate witness, has to provide oral and written informed consent.

        Exclusion Criteria:

          -  On ART less than 6 months

          -  On protease-inhibitor containing ART or any other second-line ART

          -  Bad adherence (self-reported at least 1 dose missing in the last 4 weeks, resp. 2
             doses of a twice-daily-regimen)

          -  Clinical WHO stage 3 or 4 at enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niklaus Labhardt, MD MIH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Tropical and Public Health Institute, Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Amstutz</last_name>
    <phone>0041794899448</phone>
    <email>alain.amstutz@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niklaus Labhardt</last_name>
    <email>n.labhardt@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seboche Hospital</name>
      <address>
        <city>Seboche</city>
        <state>Butha-Buthe</state>
        <zip>400</zip>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bienvenu Nsakala, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Butha-Buthe Hospital, ART clinic (Paballong)</name>
      <address>
        <city>Butha-Buthe</city>
        <zip>400</zip>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bienvenu Nsakala, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Lesotho</country>
  </location_countries>
  <link>
    <url>https://visibleimpact.org/projects/1261-molecular-hiv-monitoring-in-lesotho).</url>
    <description>Molecular HIV Monitoring in Lesotho - The Viral Load Database</description>
  </link>
  <link>
    <url>https://visibleimpact.org/projects/1197-cascade-trial</url>
    <description>The CASCADE-trial (the previous project)</description>
  </link>
  <reference>
    <citation>UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed April 10, 2016.</citation>
  </reference>
  <reference>
    <citation>TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibé B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouamé E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundzé S, Hawerlander D, Ani A, Dembélé F, Koné F, Guéhi C, Kanga C, Koule S, Séri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semdé C, Kouame A, Massumbuko JM, Chêne G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholié SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20.</citation>
    <PMID>26193126</PMID>
  </reference>
  <reference>
    <citation>INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.</citation>
    <PMID>26192873</PMID>
  </reference>
  <reference>
    <citation>Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.</citation>
    <PMID>21767103</PMID>
  </reference>
  <reference>
    <citation>Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar-Manning E, Sabin D, McCauley M, Gamble T, Zhang XC, Eron JJ, Gallant JE, Kumwenda J, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim J, Badal-Faesen S, Akelo V, Hosseinipour MC, Santos BR, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Mayer KH, Chen YQ, Cohen MS, Eshleman SH. Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):304-9. doi: 10.1097/QAI.0000000000000951.</citation>
    <PMID>26859828</PMID>
  </reference>
  <reference>
    <citation>Jones A, Cremin I, Abdullah F, Idoko J, Cherutich P, Kilonzo N, Rees H, Hallett T, O'Reilly K, Koechlin F, Schwartlander B, de Zalduondo B, Kim S, Jay J, Huh J, Piot P, Dybul M. Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet. 2014 Jul 19;384(9939):272-9. doi: 10.1016/S0140-6736(13)62230-8. Epub 2014 Apr 14.</citation>
    <PMID>24740087</PMID>
  </reference>
  <reference>
    <citation>Piot P, Abdool Karim SS, Hecht R, Legido-Quigley H, Buse K, Stover J, Resch S, Ryckman T, Møgedal S, Dybul M, Goosby E, Watts C, Kilonzo N, McManus J, Sidibé M; UNAIDS–Lancet Commission. Defeating AIDS--advancing global health. Lancet. 2015 Jul 11;386(9989):171-218. doi: 10.1016/S0140-6736(15)60658-4. Epub 2015 Jun 24. Review. Erratum in: Lancet. 2015 Jul 11;386(9989):136.</citation>
    <PMID>26117719</PMID>
  </reference>
  <reference>
    <citation>WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; Recommendations for a public health approach - Second edition June 2016. http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1. Accessed October 3, 2016.</citation>
  </reference>
  <reference>
    <citation>Lesotho 2016 National ART Guidelines - LesothoARTGuidelinesAllChaptersandAnnex2016.pdf. http://www.hivpolicywatch.org/duremaps/data/guidelines/LesothoARTGuidelinesAllChaptersandAnnex2016.pdf. Accessed September 15, 2016.</citation>
  </reference>
  <reference>
    <citation>2015_eacsguidelines_8_0-english_rev-20160124.pdf. http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf. Accessed March 28, 2016.</citation>
  </reference>
  <reference>
    <citation>Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12;316(2):191-210. doi: 10.1001/jama.2016.8900.</citation>
    <PMID>27404187</PMID>
  </reference>
  <reference>
    <citation>Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012 Nov;56(11):5998-6000. doi: 10.1128/AAC.01217-12. Epub 2012 Aug 13.</citation>
    <PMID>22890763</PMID>
  </reference>
  <reference>
    <citation>Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ Jr. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011 Aug 15;204(4):515-20. doi: 10.1093/infdis/jir353.</citation>
    <PMID>21791652</PMID>
  </reference>
  <reference>
    <citation>Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014 Jul;58(7):3585-98. doi: 10.1128/AAC.00076-14. Epub 2014 Apr 14.</citation>
    <PMID>24733471</PMID>
  </reference>
  <reference>
    <citation>PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31.</citation>
    <PMID>21288774</PMID>
  </reference>
  <reference>
    <citation>Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010 May 1;201(9):1303-7. doi: 10.1086/651618.</citation>
    <PMID>20350161</PMID>
  </reference>
  <reference>
    <citation>Labhardt ND, Bader J, Lejone TI, Ringera I, Hobbins MA, Fritz C, Ehmer J, Cerutti B, Puga D, Klimkait T. Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings. Medicine (Baltimore). 2016 Jul;95(28):e3985. doi: 10.1097/MD.0000000000003985.</citation>
    <PMID>27428189</PMID>
  </reference>
  <reference>
    <citation>Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JS, Harrigan PR, Gonzalez-Serna A. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014 May 15;28(8):1125-34. doi: 10.1097/QAD.0000000000000203.</citation>
    <PMID>24451160</PMID>
  </reference>
  <reference>
    <citation>Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Hirschel B, Phillips AN, Telenti A; Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002 Sep 27;16(14):1967-9.</citation>
    <PMID>12351960</PMID>
  </reference>
  <reference>
    <citation>Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7):927-36.</citation>
    <PMID>19043927</PMID>
  </reference>
  <reference>
    <citation>Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, Gill MJ, Schwarze-Zander C, Hernandez-Novoa B, Obel N, Kirk O, Abgrall S, Guest J, Samji H, D'Arminio Monforte A, Llibre JM, Smith C, Cavassini M, Burkholder GA, Shepherd B, Crane HM, Sterne J, Morlat P. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015 Jan 28;29(3):373-83. doi: 10.1097/QAD.0000000000000544. Erratum in: AIDS. 2015 Sep 10;29(14):1907.</citation>
    <PMID>25686685</PMID>
  </reference>
  <reference>
    <citation>García-Gascó P, Maida I, Blanco F, Barreiro P, Martín-Carbonero L, Vispo E, González-Lahoz J, Soriano V. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008 Mar;61(3):699-704. doi: 10.1093/jac/dkm516. Epub 2008 Jan 12.</citation>
    <PMID>18192682</PMID>
  </reference>
  <reference>
    <citation>Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013 Nov;57(10):1489-96. doi: 10.1093/cid/cit529. Epub 2013 Aug 14.</citation>
    <PMID>23946221</PMID>
  </reference>
  <reference>
    <citation>Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther. 2011;16(6):853-61. doi: 10.3851/IMP1819.</citation>
    <PMID>21900717</PMID>
  </reference>
  <reference>
    <citation>Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, Bangsberg DR, Yiannoutsos CT, Deeks SG, Martin JN. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014 Sep 10;28(14):2097-107.</citation>
    <PMID>24977440</PMID>
  </reference>
  <reference>
    <citation>Lesotho Demographic and Health Survey 2014 [FR309] - FR309.pdf. http://dhsprogram.com/pubs/pdf/FR309/FR309.pdf. Accessed July 30, 2016.</citation>
  </reference>
  <reference>
    <citation>Williams BG, Gouws E, Somse P, Mmelesi M, Lwamba C, Chikoko T, Fazito E, Turay M, Kiwango E, Chikukwa P, Damisoni H, Gboun M. Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets. Curr HIV/AIDS Rep. 2015 Jun;12(2):196-206. doi: 10.1007/s11904-015-0264-x. Review.</citation>
    <PMID>25929961</PMID>
  </reference>
  <reference>
    <citation>Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929-38. doi: 10.1097/QAD.0b013e328351f5b2. Review.</citation>
    <PMID>22313953</PMID>
  </reference>
  <reference>
    <citation>Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 Sep 15;214(6):873-83. doi: 10.1093/infdis/jiw219. Epub 2016 Jul 11.</citation>
    <PMID>27402780</PMID>
  </reference>
  <reference>
    <citation>Chkhartishvili N, Sharvadze L, Dvali N, Karchava M, Rukhadze N, Lomtadze M, Chokoshvili O, Tsertsvadze T. Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia. AIDS Res Ther. 2014 Jul 7;11:18. doi: 10.1186/1742-6405-11-18. eCollection 2014.</citation>
    <PMID>25035708</PMID>
  </reference>
  <reference>
    <citation>Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 1;209(5):711-20. doi: 10.1093/infdis/jit411. Epub 2013 Aug 13.</citation>
    <PMID>23943851</PMID>
  </reference>
  <reference>
    <citation>Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014.</citation>
    <PMID>24625508</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>September 30, 2017</last_update_submitted>
  <last_update_submitted_qc>September 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Tropical &amp; Public Health Institute</investigator_affiliation>
    <investigator_full_name>Amstutz Alain</investigator_full_name>
    <investigator_title>Niklaus Labhardt, MD MIH, head of the research consortium</investigator_title>
  </responsible_party>
  <keyword>randomized clinical trial</keyword>
  <keyword>low level viremia</keyword>
  <keyword>lesotho</keyword>
  <keyword>resource-limited setting</keyword>
  <keyword>ART first-line failure</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD (baseline characteristics, outcomes, follow-up data) will eventually be shared after completion of the study upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

